# Combination of Cisplatin, Docetaxel and Bevacizumab in Patients With Non-small Cell Lung Carcinoma (NSCLC)

> **NCT01368848** · PHASE2 · COMPLETED · sponsor: **Arbeitsgemeinschaft medikamentoese Tumortherapie** · enrollment: 7 (actual)

## Conditions studied

- NSCLC

## Interventions

- **DRUG:** Bevacizumab
- **DRUG:** Cisplatin
- **DRUG:** Docetaxel

## Key facts

- **NCT ID:** NCT01368848
- **Lead sponsor:** Arbeitsgemeinschaft medikamentoese Tumortherapie
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-04
- **Primary completion:** 2012-12
- **Final completion:** 2012-12
- **Target enrollment:** 7 (ACTUAL)
- **Last updated:** 2013-08-30

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01368848

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01368848, "Combination of Cisplatin, Docetaxel and Bevacizumab in Patients With Non-small Cell Lung Carcinoma (NSCLC)". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT01368848. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*